HGH Fragment 176-191

What HGH Fragment 176-191 Does

HGH Fragment 176-191 (HGH Frag) is a synthetic peptide corresponding to the C-terminal region of human growth hormone — specifically amino acids 176 through 191. This 16-amino-acid sequence is the portion of the HGH molecule responsible for its lipolytic (fat-burning) activity. By isolating this fragment from the full 191-amino-acid GH molecule, researchers created a peptide that stimulates fat breakdown without the growth-promoting, IGF-1-elevating, or insulin-disrupting effects of full growth hormone.

The research originated from work by Ng and Borstein at Monash University in Australia, who identified that the C-terminal region of HGH contained an independent fat-metabolizing domain. Their work demonstrated that this fragment could stimulate lipolysis in isolated fat cells with potency comparable to full HGH — but without activating the GH receptor or triggering IGF-1 production.

The mechanisms that matter:

• Beta-3 adrenergic receptor activation on adipocytes — directly stimulates the breakdown of stored triglycerides into free fatty acids and glycerol. This is the same fat-burning mechanism employed by full HGH, isolated to a single peptide fragment. The effect is most pronounced on visceral and subcutaneous abdominal fat
• Lipogenesis inhibition — blocks the re-esterification of fatty acids back into triglycerides. The body mobilizes fat AND resists re-storing it, creating a net lipolytic effect
• No GH receptor activation — HGH Frag 176-191 does not bind the GH receptor. This means zero IGF-1 stimulation, zero insulin resistance, zero organ growth, zero cellular proliferation. The safety implications are significant — you get fat loss without any of the metabolic disruptions of full HGH
• No impact on blood sugar — unlike full HGH (which causes insulin resistance and can elevate fasting glucose), the fragment has no effect on glucose metabolism or insulin sensitivity. This has been confirmed in multiple research settings
• Insulin-dependent activity — the fragment’s lipolytic effect is suppressed by insulin. This is why fasting is mandatory — in a fed state, elevated insulin directly counteracts the fat-mobilizing signal

HGH Fragment 176-191 vs Related Compounds

Understanding where HGH Frag fits relative to its cousins:

Feature	HGH Fragment 176-191	AOD-9604	Full HGH	GH Secretagogues
What it is	Unmodified HGH tail (aa 176-191)	Modified HGH tail (tyrosine addition)	Full 191-amino-acid hormone	Peptides that trigger GH release
Fat loss mechanism	Direct lipolysis (beta-3 AR)	Direct lipolysis (beta-3 AR)	Lipolysis + metabolic increase	Indirect via GH elevation
IGF-1 increase	No	No	Yes (significant)	Yes (modest–moderate)
Insulin resistance	No	No	Yes (dose-dependent)	Mild (from GH elevation)
Muscle growth	No	No	Yes	Yes (via IGF-1)
Side effect profile	Minimal	Minimal	Significant at high doses	Peptide-dependent
Clinical data	Limited	Phase 2 trial data	Extensive	Varies by peptide
Best for	Targeted fat loss only	Targeted fat loss only	Everything (with cost)	GH optimization broadly

Key insight: HGH Fragment 176-191 and AOD-9604 are essentially the same molecule with a minor structural modification. AOD-9604 has more published clinical data because it was developed by Metabolic Pharmaceuticals (now Calzada) through formal pharmaceutical channels. In practice, injectable HGH Frag 176-191 and injectable AOD-9604 produce very similar lipolytic effects.

When to use HGH Frag 176-191: You want targeted fat loss without any growth hormone effects. You are already relatively lean (sub-20% body fat) and trying to address stubborn fat areas. You want to avoid IGF-1 elevation, insulin resistance, and the other metabolic effects of full GH therapy.

When full HGH or GH peptides are better: You want the full spectrum of GH benefits — muscle growth, recovery, anti-aging, sleep improvement, collagen synthesis — not just fat loss. The fragment gives you one chapter of the GH book. If you want the whole book, use GH secretagogues.

Dosing Protocol

Standard Protocol

Parameter	Detail
Dose	250–500 mcg per injection
Frequency	Twice daily
Timing	Morning (fasted upon waking) + pre-bed (2+ hours after dinner)
Route	Subcutaneous injection (abdomen preferred)
Cycle length	8–12 weeks on, 4 weeks off

Dose Tiers

Level	Dose Per Injection	Daily Total	Best For
Conservative	250 mcg, 2x daily	500 mcg/day	Standard fat loss protocol, cost-effective
Standard	300 mcg, 2x daily	600 mcg/day	Common middle ground
Aggressive	500 mcg, 2x daily	1,000 mcg/day	Maximum lipolytic effect, higher cost

Start at 250 mcg twice daily. The dose-response curve for lipolysis flattens above 500 mcg per injection. Higher doses increase cost without proportionally increasing fat loss.

Why Twice Daily

HGH Fragment 176-191 has a short half-life (approximately 30 minutes in circulation), and its lipolytic effect requires sustained signaling over time to produce measurable fat loss. Twice-daily dosing ensures the fat cells receive two distinct lipolytic signals per day:

1. Morning dose (upon waking) — fasted overnight, insulin is low, free fatty acid mobilization is already primed. The fragment amplifies this natural fasted lipolytic state
2. Pre-bed dose (2+ hours after dinner) — insulin has cleared from the evening meal, creating a second fasted lipolytic window. Fat mobilization continues overnight during sleep

Some advanced users add a third dose pre-workout (fasted training) to further amplify exercise-induced fat oxidation.

Fasting Requirements

This is the single most important practical detail for HGH Fragment 176-191. Without fasting, the peptide does not work:

• Inject only in a fasted state — minimum 2 hours without food. Insulin is the master switch for lipolysis. When insulin is elevated, beta-3 adrenergic stimulation is overridden
• Wait 30+ minutes after injection before eating — allow the lipolytic signal to engage. 60 minutes is better
• Morning window: Inject immediately upon waking, before coffee with calories, before breakfast. Black coffee and water are fine
• Evening window: Stop eating 2+ hours before bed. Inject, then sleep through the fasted lipolytic window
• Fasted cardio synergy: Inject 30 minutes before low-intensity fasted cardio (walking, cycling). The fragment mobilizes fatty acids; the exercise burns them. This is the highest-yield protocol for stubborn fat

Reconstitution

For a 5 mg vial — add 2.5 mL bacteriostatic water:

Dose Per Injection	Volume to Draw
250 mcg	12.5 units on insulin syringe
300 mcg	15 units
500 mcg	25 units

Concentration: 2,000 mcg/mL. A 5 mg vial lasts 5–10 days depending on dose (at 500 mcg 2x daily, one vial lasts 5 days).

Injection site: Abdomen (subcutaneous). Some practitioners advocate injecting near the target fat area — there is anecdotal evidence that localized lipolysis may be slightly enhanced near the injection site, though this is not definitively proven in controlled studies.

Storage: Refrigerate at 2–8°C. Use within 28 days of reconstitution. Unreconstituted powder can be frozen for long-term storage. HGH Frag 176-191 is relatively fragile compared to other peptides — handle gently during reconstitution (stream water down the vial wall, do not agitate).

Cycling

• Standard: 8–12 weeks on, 4 weeks off
• Rationale: Cycling allows for assessment of results and prevents potential receptor accommodation. There is no strong evidence of tolerance development, but cycling is standard practice
• Extended protocols: Some users run 12–16 weeks, particularly when combined with a structured fat loss diet and exercise program
• Off-cycle: Fat loss gained during the cycle is maintained through diet and exercise. The fragment does not cause metabolic rebound

What to Expect

Realistic Timeline

• Weeks 1–2: No visible changes. The peptide is working at the cellular level — lipolysis is occurring, but the amount of fat mobilized takes weeks to become visible. Fasted cardio may feel slightly more productive
• Weeks 2–4: Subtle changes in stubborn areas. Waist measurements may decrease by 0.5–1 inch. Clothes may fit slightly differently. The changes are real but not dramatic
• Weeks 4–8: Visible improvement in body composition for users who are already relatively lean. Lower abdominal fat, love handles, and oblique areas respond most noticeably. Users combining with fasted cardio see the best results in this window
• Weeks 8–12: Maximum effect from the cycle. Total fat reduction of 1–3 kg of pure fat in targeted areas. The results are meaningful for someone going from 18% to 14% body fat but will not satisfy someone expecting 30-pound weight loss

Who Gets the Best Results

• Already lean (sub-20% body fat) — the fragment excels at addressing stubborn fat that resists diet and exercise alone. Lower body fat percentages mean the targeted effect is more visible
• Consistent fasting protocol — users who rigorously maintain the fasted injection windows see significantly better results than those who are inconsistent
• Combined with fasted cardio — the fat mobilization + fat oxidation combination produces measurably more fat loss than the fragment alone
• Caloric maintenance or mild deficit — the fragment mobilizes fat, but a caloric surplus will re-store it

Who is Disappointed

• Overweight individuals seeking major weight loss — HGH Frag is a scalpel, not a chainsaw. If you need to lose 20+ pounds, use semaglutide or tirzepatide
• Users who don’t fast properly — injecting in a fed state renders the peptide ineffective. This is the most common reason for poor results
• Users expecting GH peptide benefits — the fragment provides ONLY fat loss. No muscle growth, no sleep improvement, no recovery enhancement, no anti-aging effects. If you want those, use GH secretagogues

What the Research Says

HGH Fragment 176-191 has a focused but meaningful research base:

Original discovery (Ng and Borstein, Monash University): The C-terminal fragment of HGH (amino acids 176-191) was identified as containing an independent lipolytic domain in the early 1990s. Ng et al. demonstrated that this fragment stimulated lipolysis in isolated murine and human adipocytes with potency comparable to full HGH but without activating the GH receptor. The fragment did not produce any of the growth-promoting, IGF-1-stimulating, or diabetogenic effects of full HGH. Published in Endocrinology and Molecular and Cellular Endocrinology.

Mechanism of action: Wu et al. confirmed that HGH Fragment 176-191 stimulates lipolysis via beta-3 adrenergic receptor activation on adipocytes, independent of GH receptor signaling. The fragment also inhibited lipogenesis (fat formation) in vitro. The dual mechanism — increased fat breakdown plus decreased fat formation — produces a net lipolytic effect. Published in Obesity Research.

AOD-9604 clinical data (the modified version): While formal clinical trials were conducted with AOD-9604 rather than the unmodified fragment, the data is directly relevant. A Phase 2 randomized controlled trial in obese subjects showed 2.6 kg of fat loss vs placebo over 12 weeks at 1 mg/day oral dosing. No changes in fasting glucose, insulin, HbA1c, or IGF-1 were observed, confirming the safety profile. Published in Regulatory Peptides.

IGF-1 independence confirmed: Multiple studies confirmed that HGH Fragment 176-191 does not increase serum IGF-1 levels, does not cause insulin resistance, and does not activate the classical GH receptor signaling cascade (JAK2/STAT5). This pharmacological separation from full HGH is the fragment’s primary safety advantage.

Fat specificity: Research demonstrated that the fragment’s lipolytic effect was most pronounced in visceral and subcutaneous abdominal adipose tissue, with less effect on other fat depots. This may explain the clinical observation that abdominal fat responds most to HGH Frag protocols.

Derek (More Plates More Dates) has covered HGH Fragment 176-191 and AOD-9604 as fat loss tools, emphasizing that they are “refinement” compounds — effective for stubborn fat in already-lean individuals but not competitive with GLP-1 drugs for significant weight loss. He notes the importance of the fasting requirement and the distinction between the fragment and full GH.

Safety

Side Effects

HGH Fragment 176-191 has one of the mildest side effect profiles of any peptide:

Side Effect	Frequency	Notes
Injection-site redness	~5%	Minor, transient. Rotate sites
Mild headache	~3%	Usually first few days only
Slight dizziness	~2%	May relate to fasted state, not the peptide itself
Localized irritation	~2%	Occasionally reported at abdominal injection sites

No serious adverse events have been reported in any research setting. No metabolic disruption. No hormonal changes. No cardiovascular effects. No appetite changes. No mood effects. No effect on sleep.

What HGH Frag 176-191 Does NOT Do

Setting expectations correctly:

• Does not increase growth hormone — it is a fragment, not a secretagogue
• Does not increase IGF-1 — no growth effects, no cancer proliferation risk from IGF-1
• Does not build muscle — purely lipolytic. No anabolic activity
• Does not cause insulin resistance — unlike full HGH
• Does not suppress appetite — no hunger signaling effects in either direction
• Does not improve sleep or recovery — those are GH receptor-mediated effects the fragment does not activate
• Does not affect thyroid function — no metabolic rate changes

Critical Warnings

Fasting compliance determines efficacy. If you don’t inject fasted, the peptide doesn’t work. This is not a suggestion — it is a pharmacological requirement. Insulin overrides beta-3 adrenergic lipolysis.

Not a substitute for caloric control. HGH Frag mobilizes fat but does not override thermodynamics. In a caloric surplus, mobilized fatty acids will be re-stored. A caloric deficit or maintenance intake is necessary for fat loss to occur.

Not FDA-approved. HGH Fragment 176-191 is not approved for human therapeutic use.

Source quality matters. The fragment is a small peptide that can be degraded by improper handling, excessive heat, or aggressive reconstitution. Only purchase from vendors providing third-party CoA with HPLC purity testing. Reconstitute gently.

Do Not Use If

• Pregnant or breastfeeding
• Under 18
• Active cancer (theoretical concern, though the fragment does not stimulate IGF-1)
• Unable to maintain fasting protocols (the peptide requires fasting to work — if you can’t fast, don’t waste it)

What Comes Next

• Compare with AOD-9604 — the modified version of this fragment — AOD-9604 Protocol
• Need more significant weight loss? — Semaglutide or Tirzepatide
• Compare all fat loss options — Weight Loss Peptides Compared and Best Peptides for Fat Loss
• Want GH benefits beyond fat loss? — MK-677 Protocol for oral GH elevation
• Use the Reconstitution Calculator for exact dosing math